Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions
Executive Summary
TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.
You may also be interested in...
Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed
Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.
Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed
Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.
Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.